GSK plc (GSK) Stock
GSK Key Statistics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
CEO: Luke Victor Miels. Company website
GSK — Frequently Asked Questions
What is the GSK stock price today?
GSK plc (GSK) trades at $50.60, down 1.23% on the day, as of Nov 12, 2026 09:30 UTC.
What is GSK plc's market cap?
GSK plc has a market capitalisation of $102.57B, calculated from the live GSK share price and shares outstanding.
What is the P/E ratio of GSK?
GSK trades at a trailing P/E of 23.43, from earnings per share of $2.16 over the last twelve months.
How much revenue does GSK plc make?
GSK plc generated revenue of $33.47B over the trailing twelve months, which puts the stock at 3.06 times sales.
Does GSK pay a dividend?
Yes. GSK plc pays a dividend yielding 3.42% on the current share price.
What is the 52-week range for GSK?
GSK has traded between $45.81 and $61.70 over the past 52 weeks, and the last price is 18.0% below that high.
Is GSK plc profitable?
Yes. GSK plc keeps 12.97% of revenue as net income over the trailing twelve months.
What is the analyst price target for GSK?
Wall Street analysts rate GSK Hold, with an average price target of $57.95, 14.5% above the current price.
What sector is GSK plc in?
GSK plc is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in GB.
Who is the CEO of GSK plc?
Luke Victor Miels is the chief executive of GSK plc, which employs 66,841 people.
Where can I track GSK in real time?
QFI Terminal shows GSK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See GSK live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GSK in Terminal See plans